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Summary Even though the majority of patients with bladder malignancies initially present with low stage
disease, the clinical epidemiology of these so-called superficial bladder tumours is not well known. In this
paper, disease characteristics at initial presentation and during follow-up are described in 1,745 primary cases
documented prospectively in the Netherlands. The risk of recurrent disease after primary treatment is very
high: in 60% of cases, at least one recurrence is diagnosed within 5 years (95% CI: 58-62%). In patients with
a small solitary pTa grade 1 tumour, the 3-year recurrence risk is 37%. In patients with multiple large high
grade pTI tumours, this risk is as high as 77%, despite a significant beneficial effect of adjuvant intravesical
chemotherapy. The actuarial risk of disease progression is 10.2% after 3 years (95% CI: 8.6-11.8%). This risk
of progression depends on the patient's age at diagnosis, tumour stage, grade, multiplicity and the presence of
dysplasia or CIS in random urothelium biopsies. The use of intravesical instillations with chemotherapy or
BCG vaccine after TUR does not prevent progressive disease, although this finding is difficult to interpret
from a non-randomised study. The 5-year relative survival in patients with superficial TCC of the bladder is
86% (95% CI: 84-88%).
Bladder cancer is a heterogeneous disease with an unpredict-
able clinical course. In urology practice, bladder cancer cases
are differentiated on the basis of the extent of bladder wall
invasion. The largest group is the group of superficial transi-
tional cell carcinomas (TCC). Patients with superficial TCC
have a fairly good prognosis with a 5-year relative survival of
80% to 90% (American Cancer Society, 1991). Therefore, the
greatest concern in these patients is not to reduce mortality
but to lower and postpone the number of recurrences (which
are very common in superficial TCC) and thereby to prevent
progression to invasive disease (Herr, 1991). To accomplish
this, initial treatment by transurethral resection (TUR) is
often followed by intravesical instillations with chemotherapy
or immunotherapy.
Until now, all knowledge of disease characteristics of
superficial bladder cancer (such as stage distribution, the risk
of recurrences and disease progression and survival) has been
based on fairly small case series which were often selective in
one or more respects. In this paper, quantitative data of
clinical epidemiological features of superficial bladder cancer
are presented from a large case series in the Netherlands.
Patients and methods
In the southeastern part of the Netherlands, there has been a
close cooperation between urologists, pathologists and radio-
therapists from 23 district hospitals, one university hospital
and six radiotherapy centres since 1981 (the Dutch South-
East Cooperative Urological Group). In 1983, this resulted in
a consensus report on the diagnosis and treatment of patients
with bladder cancer. Furthermore, it was agreed that the
participating urologists would document every newly diag-
nosed bladder cancer patient. This documentation project
started in 1983. Intake registration continued until January
1990. Follow-up registration continued until July 1991.
The following items of each patient with a primary bladder
tumour were registered: date of birth, sex, date of histological
confirmation, main complaint, tumour morphology, grade of
differentiation (according to the WHO grading system: Mos-
tofi, 1973), localisation, TNM classification (UICC, 1978),
tumour multiplicity and intravenous urogram result. Further-
more, all participating urologists were asked to take (and
document) at least four random quadrant biopsies in macro-
scopically normal-looking urothelium (left and right lateral
wall, trigone and dome) at the time of resection of the
tumour(s). The therapy to be applied was transurethral resec-
tion of the tumour (TUR) in all patients. Urologists were
advised to consider adjuvant intravesical instillations with
chemotherapy or BCG vaccine in the case of multiple
tumours. In pTI grade 3 patients more aggressive therapy,
such as radical surgery or external or interstitial radio-
therapy, would have to be considered. To detect recurrences,
cystoscopy and urine cytology were used every 3 months in
the first year after treatment. From the second year onwards,
this check-up was performed every 6 months. Follow-up data
concerning disease and life status were collected for each
patient once every year.
Between 1983 and 1990, 2,805 cases were documented. In
1991, all the data in the documentation project were reviewed
using the medical files. After this check, the records of 100
cases were excluded. Of these, 30 had an inverted papilloma
(which was considered to be benign), 58 had recurrent in-
stead ofprimary disease at first registration, five did not have
TCC in the bladder but in the upper urinary tract. In the
records of seven cases, there were major inconsistences,
which could not be corrected with information from the
medical files. Of the remaining 2,705 cases, 1,745 (64.5%)
had superficial TCC. 'Superficial' is defined as tumour exten-
sion limited to the mucosa (pTa) or the lamina propria (pTl)
of the bladder wall with or without carcinoma in situ in
random biopsies. In urology practice, primary carcinoma in
situ (pTis) is considered to be very different from pTa and
pTI tumours because of its relatively aggressive clinical
behaviour. For that reason, patients with primary pTis
(n = 52 in our series) were not evaluated in this study. Sur-
vival free of recurrence, survival free of progression and
survival itself were measured from the data of histological
diagnosis to the date of first recurrence, first evidence of
disease progression and the date of death, respectively. Sur-
vival curves were based on the life table method, statistical
significance being determined by the log rank test. The inde-
pendence of host and tumour characteristics in determining
survival free of recurrence and progression was evaluated
multivariately using the Cox proportional hazards model
(Cox, 1972).
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Although the case series in this documentation project is
large, registration was not population based, which implies
that incidence rates cannot be calculated from the project.
However, nine Comprehensive Cancer Centres in the Nether-
lands keep population based regional cancer registries (IKL),
covering a population of approximately 850,000 in the
southern part of the Netherlands, has complete data on the
incidence of superficial bladder cancer since 1986 (Schouten
et al., 1992). Information from this registry from the period
1986-1989 was used to calculate age and sex-specific inci-
dence rates. The population based cancer registry was also
used to check whether patient intake in the documentation
project was selective in any way. There appeared to be hardly
any difference in age, sex, stage and grade distribution
between the cancer registry and our case series, indicating no
under or over representation in our series.
Results
Incidence
In the southern part of the Netherlands, the total bladder
cancer incidence rate per 105 person-years (age-standardised
to the European standard population) is 36.3 for males and
6.7 for females. Superficial bladder cancer incidence rates for
males and females are 23.7 and 3.9, respectively. This
accounts for 65% of the total bladder cancer incidence in
males and 58% in females. The proportion of all bladder
cancers diagnosed as superficial disease is higher in the
younger age categories than in the older ones (Figure 1). In
males, the lifetime risk of developing bladder cancer (before
the age of 75 years) is 2.8%. The risk of superficial bladder
cancer is 1.9%. In females, these risks are 0.5% and 0.4%,
respectively.
Initialpresentation
In the documentation project, 1,745 patients with superficial
(pTa or pTl) TCC were registered. Characteristics of this
group of patients at initial presentation are listed in Table I:
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32% of all the patients had a pTI tumour; 16% of the
tumours were classified with differentiation grade 3 and 29%
had multiple tumours. Random biopsies of macroscopically
normal-looking urothelium were taken in 1,044 patients. In
22% of these patients, dysplasia or carcinoma in situ was
diagnosed in at least one biopsy specimen. The median age at
the time of diagnosis was 67 years. There was a clear shift
towards a higher disease stage with increasing age (Figure 2).
In patients under the age of 40 years, pTa grade 1 or 2
disease accounted for more than 85% compared to only 52%
in patients over 80 years of age. The proportion of patients
diagnosed with multiple tumours was also different for these
age groups: 13% vs 37%.
From the total group of patients, 64% were treated with
transurethral resection only; additional intravesical instilla-
tions were administered in 32% of the cases and more exten-
sive therapy was given in 4% of the cases (radiotherapy
and/or cystectomy). The latter 4% were excluded from the
analysis of the risks of recurrence and progression.
First recurrence
The life-table (or actuarial) risk of recurrent disease after
primary treatment in superficial bladder cancer was very
high. Within 5 years, nearly 60% of all the cases had at least
one recurrence (Figure 3). A proportion of this group of
patients with a recurrence were prone to having more recur-
rences. The risk of recurrent disease in the first year of
follow-up was 33% (95% CI: 31-35%). In the second year
of follow-up, this risk was as high as 47% among the
patients who had already had recurrent disease, compared to
only 18% of the patients without recurrence in the first year
of follow-up.
The risk of recurrent disease in superficial bladder cancer
was dependent on a number of prognostic indicators. In the
univariate analyses, tumour stage (pTl vs pTa), degree of
differentiation (grade 3 vs 2 vs 1), multiplicity (multiple vs
solitary) and extent of the tumour (involvement ofmore than
one bladder area vs 1 area) had statistically significant effects
on the risk of recurrence (all log-rank tests yielded P
values<0.001). In our study, the risk of recurrence was not
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Figure 1 Age-specific incidence rates of total bladder cancer and superficial bladder cancer in males and females in the province of
Limburg (NL), 1986-1989.
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TableI Clinicalcharacteristics atdiseasepresentation andthetherapy
applied in 1,745 patients with primary superficial TCC
n %
Sex
Men
Women
Age
< = 39
40-49
50-59
60-69
70-79
80+
Main complaint (n= 1227)
Haematuria
Irritative bladder symptoms
Not urological
Stage
pTa
pTI
Gradea
1
2
3
Multiplicity
Solitary
Multiple
Unknown
Areas involved
Neck only
Trigone only
Posterior wall only
Right lateral wall only
Left lateral wall only
Dome only
Anterior wall only
2 Areas
3 Areas
>=4 Areas
Quadrant biopsies (n = 1044)
No abnormalities
Dysplasia in 1 or more areas
Carcinoma in situ
Therapy
TUR only
TUR + instillations
(Partial) cystectomy or interstitial
radiotherapy
1415
330
46
103
295
550
546
205
991
156
80
1187
558
669
793
283
1223
510
12
27
55
123
384
390
38
25
373
166
164
816
142
86
1116
558
71
81.1
18.9
2.6
5.9
16.9
31.5
31.3
11.7
80.8
12.7
6.5
68.0
32.0
38.4
45.4
16.2
70.1
29.2
0.7
1.5
3.2
7.0
22.0
22.3
2.2
1.4
21.4
9.5
9.4
78.2
13.6
8.2
64.0
32.0
4.1
aIn cases with different grades in one tumour, the highest grade was
documented.
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significantly different in male and female patients (P = 0.56)
and in patients younger and older then 70 years of age
(P = 0.93). The risk in patients with concomitant dysplastic
abnormalities in normal-looking urothelium was only slightly
higher than the risk in patients without these abnormalities:
57% and 51%, respectively (P=0.10).
Even though intravesical chemotherapy or BCG was appli-
ed more frequently in patients with a poor prognostic profile,
adjuvant therapy proved to be effective for preventing recur-
rences. In the patients who were treated with TUR alone, the
3-year risk of recurrence was 55%, whereas this risk was
49% (P = 0.005) in the cases treated with intravesical instilla-
tions.
We subsequently re-evaluated all the factors in a multi-
variate proportional hazards regression model. In this model,
we also adjusted for the potential distorting effect of adju-
vant intravesical chemotherapy. The results remained prac-
tically the same compared to those from the univariate
analyses. Tumour stage, grade, extent and multiplicity had
statistically significant independent prognostic value regard-
ing the risk of first recurrence (see Table II). The administra-
tion of intravesical therapy reduced this risk. When analysed
multivariately, however, the result of random biopsies had no
significant prognostic value: the relative risk of urothelial
dysplasia or CIS compared to normal urothelium was only
1.11 (95% CI: 0.89-1.39).
Patients with the most favourable prognostic profile may
therefore be defined as those with a solitary pTa grade 1
tumour located in just one area. In our study cohort, 390
patients had such a favourable score on all four factors. The
3-year risk in this group of patients (20% of whom were
treated with intravesical instillations) was 37%. In the prog-
nostically least favourable group of 55 patients with multiple
pTl grade 3 tumours located in more than one area, the
3-year risk was as high as 77%, even though 69% of these
patients were treated adjuvantly.
Progression
In the documentation project, disease progression was defin-
ed as a shift to a higher stage category (or the development
of metastases). The 3-year actuarial risk of progressive
disease was 10.2% (95% CI: 8.6-11.8%). After 5 years, this
risk had hardly increased: 13.3%. As is the case with the risk
of recurrence, tumour stage, grade, extent and multiplicity
appeared to have prognostic significance for the risk of pro-
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Figure 2 Distribution (%) of stage and grade by age category in patients with superficial TCC of the bladder.
*= .INE - A=
A.SUPERFICIAL BLADDER CANCER
100
80
60
40
20
0
0 1 2 3 4 5 6 7
Follow-up (years)
Number of patients = 1722 (cystectomy patients were excluded)
Figure 3 Actuarial risk (%) of recurrent disease in patients with superficial TCC of the bladder (with 95% confidence interval).
Table II Results of the multivariate proportional hazards regression
model on the risk of first recurrence
95% Confidence
Factor Relative risk interval
Sex:
Male vs female 1.01 0.84-1.21
Age:
=>70 vs <70 0.92 0.80-1.06
Tumour stage:
pTl vspTa 1.38 1.16-1.65
Tumour grade:
2 or 3 vs 1 1.22 1.04-1.43
Tumour extent:
=>2 areas vs 1 1.34 1.14-1.57
Multiplicity:
Multiple vs solitary 1.42 1.21-1.67
Random biopsies:.
Dysplasia/CIS vs normal 1.11 0.89-1.39
Therapy:
Instillations vs TUR alone 0.67 0.57-0.80
aInthemodel,aseparatebiopsycategory wasincluded forthepatients
from whom no biopsies were taken.
gression. Furthermore, the 3-year risk in patients older than
70 years was 12.7%, whereas this risk was only 7.4% in
patients younger than 70 years of age (P =0.001).
Concomitant intraurothelial dysplasia or CIS significantly
increased the risk of progression. In patients with such
abnormalities the risk was 21%, whereas this risk was only
7% in patients without dysplastic abnormalities (P<0.001).
Contrary to the effect on recurrence, intravesical instillations
did not lower the risk of progression. Because the group of
patients who received adjuvant therapy had a poorer prog-
nostic profile, the risk of progression in this group was even
higher than in the patients treated with TUR alone (12% vs
8%).
Except for tumour extent, all the factors with prognostic
value in the univariate analyses retained their statistically
significantly quality in the multivariate regression model.
Survival
The actuarial risk of dying within 5 years after diagnosis was
25% (95% CI: 23-27%) (Figure 4). This risk has to be
compared to the expected risk of dying from all causes given
the age and sex distribution of this group of patients. Using
data from the Registration of Causes of Death from the
Dutch Central Bureau of Statistics, we calculated the expect-
ed risk to be 13%. Therefore, the relative 5-year survival of
patients with superficial bladder cancer was (100-25)/(100-
13) = 86%. Thus, the excess risk of dying within 5 years was
approximately 14%.
Discussion
The reported distributions of disease characteristics at initial
diagnosis in our patients with primary superficial TCC, may
not be representative for the situation in other countries.
Especially the distribution of grade and cold biopsy results
may differ because there are not yet any objective criteria
available to enable all pathologists to classify urothelium
specimens in a reproducible manner (Jordan et al., 1987;
Pauwels et al., 1988; Richards et al., 1991). Although the
stage distribution is believed to be a better measure for
comparison, different interpretations of the pT category by
different pathologists are also possible (Abel et al., 1988a;
Kurth et al., 1989; Parmar et al., 1989; Herr & Jakse, 1991).
Another factor which very often influences the distribution of
disease characteristics is the inclusion of patients with recur-
rent instead of primary disease. Over the past 15 years, it is
likely that an increasing number of 'papillomas' have been
classified as papillocarcinomas (until 1978, the UICC listed
only the category pTl for superficial bladder cancer). For
this reason, comparison with other case series is only worth-
while if these series were documented fairly recently. In a
recent study by Abel, 107 (62.6%) out of the 171 cases with
bladder cancer had superficial disease at presentation (Abel
et al., 1988b). Of these, 71% were classified as pTa. From the
total group, 60.7% (compared to 70.1% in our study) had
solitary tumours. Grade 1, 2 and 3 accounted for 6.5%,
85.0% and 8.4% of all the tumours, respectively. This distri-
bution, which is very different from the finding in our study,
illustrates the need for better reproducible methods for the
assessment of certain indicators used for prognosis. In a
recent Danish study, 61% of 500 bladder cancer cases had
superficial disease, of whom 69% had stage pTa (Wolf et al.,
1987). These numbers are very similar to those in our study.
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Figure 4 Actuarial survival (%) in patients with superficial TCC of the bladder (with 95% confidence interval) compared to the Dutch population.
In the Danish case series, 7.9% of the pTa/pT1 patients had
carcinoma in situ in the cold-cup biopsy specimens taken at
the first presentation of disease. Another 15.4% showed
atypia grade 2. In a study by Flamm and Dona, CIS was
found in the quadrant biopsy specimens in 6% of 216
patients. Dysplasia was found in 18% (Flamm & Dona,
1989). In our study, the corresponding percentages were 8.2
and 13.6, respectively. In a recent study by Solsona et al.
(1991), 48 out of the 306 patients with superficial bladder
tumours had associated carcinoma in situ, but this high
number was caused by the inclusion of random area as well
as suspicious area biopsies.
Nearly 60% of all the patients in our study had at least
one recurrence within 5 years; most of them within 2 years
(2-year recurrence risk: 45%). In fact, the recurrence risk in
superficial bladder cancer is so high that (as opposed to other
cancer sites) a second occurrence of TCC in the bladder is
always interpreted as a recurrence, although this is theoret-
ically incorrect (Abel, 1988). The recurrence risk is dependent
on a number ofprognostic factors (Abel, 1988; Lum & Torti,
1991). In our case series, we studied the effect of seven
prognostic factors and found that tumour stage, grade,
extent and multiplicity were statistically significant prognostic
indicators. Using these indicators, it may be possible to
discern groups of patients with very different risks of recur-
rence. This, however, does not mean that it will be possible
to predict the risk of individual patients fairly accurately.
After all, for an individual patient there are only two possible
outcomes: either he suffers a recurrence or he does not. Until
we are able to differentiate all superficial bladder cancer
patients into one group with a 100% recurrence risk and one
group with a 0% recurrence risk, predictions for individuals
will always be inaccurate (Levine et al., 1991). The finding in
our project that even the best prognostic group still had a
3-year recurrence risk of 37%, rather than 0%, shows that
the inaccurate measurement of prognostic indicators together
with biological variablility inevitably leads to inaccurant pre-
dictions. Although we have a number of highly significant
prognostic indicators for the risk of recurrence, apparently
we do not have enough of these indicators yet.
Superficial bladder cancer patients have a relatively high
survival rate. In our study, the 5-year survival was 75%,
compared to 87% for the Dutch population adjusted for age,
sex and calendar period. This finding is very similar to the
88% 5-year survival rate for early stage bladder cancer
(adjusted for normal life-expectancy) in the USA (American
Cancer Society, 1991). In a recent study in the United King- dom, the 5-year survival in 150 pTa and 85 pTa patients was
80 and 69%, respectively (Gulliford et al., 1991). Flamm and
Havelec (1990) found a tumour-related mortality rate of
12.5% in 345 patients with primary superficial TCC treated
with TUR and intravesical instillations.
Despite the fact that the excess mortality in superficial
bladder cancer is small, it may be asked why there is any
excess mortality at all. Theoretically, it is possible that some
of the superificial bladder cancers were already higher stage
cancers at initial diagnosis. It is not exceptional for the
pathologist to receive a resection specimen that does not
contain any muscle tissue. Thus, some T2 tumours (with a
poorer prognosis) may have been staged as pTI tumours. In
the surveillance programme of the USA National Bladder
Cancer Collaborative Group, for example, there was no mus-
cle tissue present in the specimens of 40 out of 95 tumours
classified as pTI (Cutler et al., 1982). By contrast, in a recent
study of Abel et al. (1988a), muscle tissue was present in
95% of the pTa/pTl biopsy specimens. Unfortunately, com-
parable information was not available in our project.
Another possible explanation for excess mortality is under-
treatment. Especially multiple high grade tumours which
extend into the lamina propria are often seen to progress to
higher stage disease (Cutler et al., 1982; Pocock et al., 1982; Heney et al., 1983). But until now, this knowledge has not
led to a consensus policy of treating all 'high risk' tumours
with (at least) intravesical instillations. According to our
data, a surprisingly high number (26%) of patients with
multiple pTl grade 3 tumours were treated with TUR only. Nevertheless, it is dubious whether intravesical instillations
prevent progression. Intravesical chemotherapy will usually
decrease the rate and number of recurrences, but according
to many authors it does not necessarily alter the ultimate
outcome of the disease (Heney, 1988; Flamm & Havelec, 1990; Newling, 1990; Soloway et al., 1990; Vogeli & Acker-
mann, 1990). Our data support the observation of these
authors. As Table III illustrates, intravesical instillations
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Table III Influence of the use of intravesical instillations for the
treatment of the primary tumour on the 5-year actuarial risk of
progressive disease'
S-year risk ofprogressive disease (%)
Intravesical Log-rank
n = 1674 TUR only instillations P value
Sex
Male 11.1 (n = 902) 14.7 (n =449) 0.05
Female 11.0 (n = 214) 19.6 (n = 109) 0.06
Age
<70 9.1 (n = 634) 14.5 (n = 314) 0.01
=>70 13.6 (n = 482) 17.0 (n = 244) 0.29
Stage
pTa 8.3 (n = 840) 10.1 (n = 339) 0.66
pTl 19.3 (n = 276) 24.7 (n = 219) 0.07
Grade
1 4.1 (n = 531) 7.7 (n= 137) 0.29
2 15.9 (n = 495) 12.0 (n = 277) 0.24
3 25.3 (n = 90) 32.2 (n = 144) 0.29
Multiplicity
Solitary 8.8 (n = 856) 10.4 (n = 325) 0.27
Multiple 18.6 (n = 254) 24.1 (n = 229) 0.32
Random biopsies
Normal 10.1 (n = 533) 7.0 (n = 260) 0.40
Dysplasia/CIS 20.2 (n = 74) 26.7 (n = 134) 0.30
aProgressivediseaseisdefinedasanyshifttoahigherstagecategoryor
the development of metastases.
seem to increase rather than decrease the 5-year risk of
progressive disease. However, this finding was caused by the
fact that more patients with a relatively poor prognosis
received adjuvant therapy. In a proportional hazards model
with sex, age, tumour stage, grade, multiplicity, random
biopsy result and therapy, the relative risk of TUR-only vs
intravesical instillations was 1.0 (95% CI: 0.7-1.3). Never-
theless, even though analysed multivariately, this finding has
to be interpreted with caution because our study was not
initiated to study therapy effects and therefore was not ran-
domised. Furthermore, most of the patients in our study who
were treated adjuvantly, received intravesical instillations
with Doxorubicin or Mitomycin-C. Intravesical immunother-
apy with Bacillus Calmette-Guerin RIVM, a strain produced
by the Dutch National Institute of Public Health and Envir-
onmental Hygiene, was applied less frequently. Two recent
studies give some indication that BCG may be more effective
in preventing progression than the chemotherapeutical agents
(Herr et al., 1988; Eure et al., 1992). Also, at the present time
t = n EORTC phase II study is going on in which a sequential
combination of intravesical chemotherapy with Mitomycin-C
and intravesical immunotherapy with BCG is evaluated in
recurrent superficial TCC of the bladder. Possibly, in the
near future such a combination regimen may appear to be
effective in delaying or preventing disease progression.
In summary, we can conclude that even superficial TCC,
as a distinct subgroup of bladder cancer, is a heterogeneous
disease with an unpredictable clinical course. Even though
some important indicators for future recurrences and pro-
gressive disease can be identified (such as tumour stage, grade
and multiplicity), it remains a challenge to find more and
stronger prognosticators which can more accurately predict
the disease outcome in individual patients. Only then will it
be possible to treat patients with a poor prognosis more
aggressively and to avoid overtreatment of patients with a
fairly good prognosis.
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